Market Overview

Ardelyx Up 50% After Positive Phase 3 Study Of Tenapanor

Related ARDX
Benzinga's Top Upgrades, Downgrades For August 24, 2018
45 Biggest Movers From Tuesday
Your Daily Pharma Scoop: XBiotech Reports Positive Data, AstraZeneca's New Approval, Novartis' Positive MS Trial (Seeking Alpha)

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by $2.63, or 48 percent, at $8.03 in Thursday's session.

After Wednesday's close, the company announced a pivotal phase 3 study of Tenapanor met its primary and secondary endpoints, supporting its NDA submission in 2018.

After a higher open, Ardelyx had a 70-cent retreat to $7.30 before continuing its move higher. The ensuing rally took the stock to $8.65. That high is just shy of its May 12 high ($8.80), which was the high for the session when it fell from its previous day's close of $12.45 to $7.45.

Interestingly, the company reported some positive results for Tenapanor at that time, but the results didn't meet the Streets expectations.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (ARDX)

View Comments and Join the Discussion!

Are There Any Cheap Tech Stocks?

Excitement Builds As The Dow Reaches For The Sky